PHLDA2 and bone neoplasm: In osteosarcoma, one type of aggressive bone tumor, PHLDA2 displayed decreased expression level, suggested a favorable prognosis for patients, and overexpressed PHLDA2 could impair tumorigenesis and metastasis both in vitro and in vivo [31, 32].